HELP Helus Pharma
Price Chart
Executive Summary
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major depressive disorder, aligning with a recent executive order on veteran mental health. The partnership is a non-financial clinical trial support agreement with no disclosed deal value, representing a routine operational update for a clinical-stage biotech.
Actionable Insight
This is a routine partnership announcement with no financial impact. Monitor HLP003 Phase 3 data readouts and regulatory milestones for stock-moving catalysts. The executive order provides tailwinds but does not change near-term fundamentals.
Key Facts
- Collaboration with TARA Mind to support recruitment for HLP003 Phase 3 program in MDD
- HLP003 has FDA Breakthrough Therapy Designation
- Partnership aligns with April 18, 2026 Executive Order on mental health treatments
- No financial terms or deal value disclosed
- HLP004 is in Phase 2 for generalized anxiety disorder
Financial Impact
No financial terms disclosed; collaboration is operational in nature
Risk Factors
- No financial commitment from TARA Mind — partnership may not materially accelerate enrollment
- Phase 3 clinical trial risks (efficacy, safety, regulatory)
- Company has no approved products and relies on future financing
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285629 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
11d ago
|
6-K
| $4.55 $4.30 | ▼ −5.49% | ▼ −4.77% | $4.30 (−5.49%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $5.15 $5.29 | ▲ +2.72% | ▲ +3.06% | $4.30 (−16.50%) |
|
Apr 30, 2026
6w ago
|
6-K
| $5.31 $5.15 | ▼ −3.01% | ▼ −3.23% | $4.30 (−19.02%) |
|
Apr 28, 2026
6w ago
|
6-K
| $5.16 $4.91 | ▼ −4.84% | ▼ −4.84% | $4.30 (−16.67%) |
|
Apr 20, 2026
7w ago
|
6-K
| $4.93 $5.77 | ▲ +17.04% | ▲ +16.02% | $4.30 (−12.78%) |
|
Apr 20, 2026
7w ago
|
6-K
| $4.93 $5.77 | ▲ +17.04% | ▲ +16.02% | $4.30 (−12.78%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $5.61 $4.93 | ▼ −12.12% | ▼ −11.47% | $4.30 (−23.35%) |
|
Apr 16, 2026
8w ago
|
6-K
| $5.50 $5.50 | · 0.00% | ▼ −1.21% | $4.30 (−21.82%) |
|
Apr 16, 2026
8w ago
|
Press Release
| $5.50 $5.50 | · 0.00% | ▼ −1.21% | $4.30 (−21.82%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $5.64 $5.25 | ▼ −6.91% | ▼ −5.60% | $4.30 (−23.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access